Loading…

Quality of life following a change in therapy for diabetes mellitus

The study objective was to evaluate and compare quality-of-life (QOL) parameters between patients with type 2 (non-insulin-dependent) diabetes mellitus who changed therapy from an oral hypoglycaemic agent (OHA) to insulin and those who remained on an OHA. The World Health Organization Quality of Lif...

Full description

Saved in:
Bibliographic Details
Published in:PharmacoEconomics 1998-08, Vol.14 (2), p.201-207
Main Authors: Pibernik-Okanović, M, Szabo, S, Metelko, Z
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c409t-da90c51cfcb89dea3a03e1c011361b872d1fa16ce157d92a1a6a50d3e37252b33
cites cdi_FETCH-LOGICAL-c409t-da90c51cfcb89dea3a03e1c011361b872d1fa16ce157d92a1a6a50d3e37252b33
container_end_page 207
container_issue 2
container_start_page 201
container_title PharmacoEconomics
container_volume 14
creator Pibernik-Okanović, M
Szabo, S
Metelko, Z
description The study objective was to evaluate and compare quality-of-life (QOL) parameters between patients with type 2 (non-insulin-dependent) diabetes mellitus who changed therapy from an oral hypoglycaemic agent (OHA) to insulin and those who remained on an OHA. The World Health Organization Quality of Life Questionnaire (WHOQOL) was used to assess quality of life among 2 groups of patients with type 2 diabetes mellitus at baseline and after a 2-month follow-up period. The study was conducted in the outpatient department of the Vuk Vrhovac Clinic, a referral centre for registration, treatment and follow-up of patients with diabetes mellitus in Zagreb, Croatia. 32 consecutively recruited patients with type 2 diabetes mellitus who were switched from an OHA to insulin therapy (group 1) were compared with 28 patients who remained on OHA (group 2) with respect to QOL issues. The patient groups were comparable in terms of gender, age, duration of disease, education and family status. However, patients in group 1 had glycosylated haemoglobin (HbA1c) values greater than 9.5% on average during a period of approximately 6 months, which was the criterion used for switching to insulin therapy. At baseline, various QOL ratings were higher among patients in group 2 than group 1, indicating better quality of life with respect to overall quality of life (t = -2.31, p = 0.03), physical health (t = -2.36, p = 0.02), psychological state (t = -2.01, p = 0.05) and level of independence (t = -2.75, p = 0.001), while no differences were found between groups with respect to the social domain, personal beliefs and environmental QOL aspects. After the follow-up period, the groups were comparable in all QOL aspects other than overall quality of life (t = -2.18, p = 0.03) and level of independence (t = -3.49, p = 0.001), both of which remained higher for patients in group 2. No changes in QOL parameters were detected within group 2 from baseline to the end of the 2-month follow-up period, whereas patients in group 1 showed significant improvement in psychological QOL determinants (t = -2.14, p = 0.04). Results of the study indicate that introducing insulin therapy in patients with type 2 diabetes mellitus and sustained elevated HbA1c levels might positively affect their quality of life.
doi_str_mv 10.2165/00019053-199814020-00008
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70027798</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70027798</sourcerecordid><originalsourceid>FETCH-LOGICAL-c409t-da90c51cfcb89dea3a03e1c011361b872d1fa16ce157d92a1a6a50d3e37252b33</originalsourceid><addsrcrecordid>eNpNUMtOwzAQtBAIyuMXkE_cArt2E8dHVPEUEkKCs-U4myaQF3EC6t_jtlBx2J2Vd2Y1HsY4wqXAJL4CANQQywi1TnEOAqLwBOkemyEqHQkQan8zQ6QSDUfs2Pv3wEikEofsCAHTZJ7AjC1eJltX44p3Ba-rgnjR1XX3XbVLbrkrbbskXrV8LGmw_SpsB55XNqORPG-oDtLJn7KDwtaezn7xhL3d3rwu7qOn57uHxfVT5Oagxyi3GlyMrnBZqnOy0oIkdIAoE8xSJXIsLCaOMFa5FhZtYmPIJQXPscikPGEX27v90H1O5EfTVN4FE7albvJGQfi20mkgpluiGzrvBypMP1SNHVYGwawDNH8Bml2AZhNgkD5upQP15Ha674-yL8l1rfky0uI8tNV6COoAVSgRql8joBGgTDk24dj5r-Epayj_52Ibv_wByYKEOQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70027798</pqid></control><display><type>article</type><title>Quality of life following a change in therapy for diabetes mellitus</title><source>Springer Nature:Jisc Collections:Springer Nature Read and Publish 2023-2025: Springer Reading List</source><creator>Pibernik-Okanović, M ; Szabo, S ; Metelko, Z</creator><creatorcontrib>Pibernik-Okanović, M ; Szabo, S ; Metelko, Z</creatorcontrib><description>The study objective was to evaluate and compare quality-of-life (QOL) parameters between patients with type 2 (non-insulin-dependent) diabetes mellitus who changed therapy from an oral hypoglycaemic agent (OHA) to insulin and those who remained on an OHA. The World Health Organization Quality of Life Questionnaire (WHOQOL) was used to assess quality of life among 2 groups of patients with type 2 diabetes mellitus at baseline and after a 2-month follow-up period. The study was conducted in the outpatient department of the Vuk Vrhovac Clinic, a referral centre for registration, treatment and follow-up of patients with diabetes mellitus in Zagreb, Croatia. 32 consecutively recruited patients with type 2 diabetes mellitus who were switched from an OHA to insulin therapy (group 1) were compared with 28 patients who remained on OHA (group 2) with respect to QOL issues. The patient groups were comparable in terms of gender, age, duration of disease, education and family status. However, patients in group 1 had glycosylated haemoglobin (HbA1c) values greater than 9.5% on average during a period of approximately 6 months, which was the criterion used for switching to insulin therapy. At baseline, various QOL ratings were higher among patients in group 2 than group 1, indicating better quality of life with respect to overall quality of life (t = -2.31, p = 0.03), physical health (t = -2.36, p = 0.02), psychological state (t = -2.01, p = 0.05) and level of independence (t = -2.75, p = 0.001), while no differences were found between groups with respect to the social domain, personal beliefs and environmental QOL aspects. After the follow-up period, the groups were comparable in all QOL aspects other than overall quality of life (t = -2.18, p = 0.03) and level of independence (t = -3.49, p = 0.001), both of which remained higher for patients in group 2. No changes in QOL parameters were detected within group 2 from baseline to the end of the 2-month follow-up period, whereas patients in group 1 showed significant improvement in psychological QOL determinants (t = -2.14, p = 0.04). Results of the study indicate that introducing insulin therapy in patients with type 2 diabetes mellitus and sustained elevated HbA1c levels might positively affect their quality of life.</description><identifier>ISSN: 1170-7690</identifier><identifier>EISSN: 1179-2027</identifier><identifier>DOI: 10.2165/00019053-199814020-00008</identifier><identifier>PMID: 10186460</identifier><language>eng</language><publisher>New Zealand: Springer Healthcare | Adis</publisher><subject>Adult ; Aged ; Antihyperglycaemics ; Diabetes Mellitus, Type 2 - drug therapy ; Diabetes Mellitus, Type 2 - psychology ; Female ; Glycated Hemoglobin A - analysis ; Health technology assessment ; Humans ; Insulin ; Insulin - therapeutic use ; Male ; Middle Aged ; Pharmacoeconomics ; Quality of Life ; Quality-of-life-rating-scales ; Type-2-diabetes-mellitus</subject><ispartof>PharmacoEconomics, 1998-08, Vol.14 (2), p.201-207</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c409t-da90c51cfcb89dea3a03e1c011361b872d1fa16ce157d92a1a6a50d3e37252b33</citedby><cites>FETCH-LOGICAL-c409t-da90c51cfcb89dea3a03e1c011361b872d1fa16ce157d92a1a6a50d3e37252b33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10186460$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttp://econpapers.repec.org/article/wkhphecon/v_3a14_3ay_3a1998_3ai_3a2_3ap_3a201-207.htm$$DView record in RePEc$$Hfree_for_read</backlink></links><search><creatorcontrib>Pibernik-Okanović, M</creatorcontrib><creatorcontrib>Szabo, S</creatorcontrib><creatorcontrib>Metelko, Z</creatorcontrib><title>Quality of life following a change in therapy for diabetes mellitus</title><title>PharmacoEconomics</title><addtitle>Pharmacoeconomics</addtitle><description>The study objective was to evaluate and compare quality-of-life (QOL) parameters between patients with type 2 (non-insulin-dependent) diabetes mellitus who changed therapy from an oral hypoglycaemic agent (OHA) to insulin and those who remained on an OHA. The World Health Organization Quality of Life Questionnaire (WHOQOL) was used to assess quality of life among 2 groups of patients with type 2 diabetes mellitus at baseline and after a 2-month follow-up period. The study was conducted in the outpatient department of the Vuk Vrhovac Clinic, a referral centre for registration, treatment and follow-up of patients with diabetes mellitus in Zagreb, Croatia. 32 consecutively recruited patients with type 2 diabetes mellitus who were switched from an OHA to insulin therapy (group 1) were compared with 28 patients who remained on OHA (group 2) with respect to QOL issues. The patient groups were comparable in terms of gender, age, duration of disease, education and family status. However, patients in group 1 had glycosylated haemoglobin (HbA1c) values greater than 9.5% on average during a period of approximately 6 months, which was the criterion used for switching to insulin therapy. At baseline, various QOL ratings were higher among patients in group 2 than group 1, indicating better quality of life with respect to overall quality of life (t = -2.31, p = 0.03), physical health (t = -2.36, p = 0.02), psychological state (t = -2.01, p = 0.05) and level of independence (t = -2.75, p = 0.001), while no differences were found between groups with respect to the social domain, personal beliefs and environmental QOL aspects. After the follow-up period, the groups were comparable in all QOL aspects other than overall quality of life (t = -2.18, p = 0.03) and level of independence (t = -3.49, p = 0.001), both of which remained higher for patients in group 2. No changes in QOL parameters were detected within group 2 from baseline to the end of the 2-month follow-up period, whereas patients in group 1 showed significant improvement in psychological QOL determinants (t = -2.14, p = 0.04). Results of the study indicate that introducing insulin therapy in patients with type 2 diabetes mellitus and sustained elevated HbA1c levels might positively affect their quality of life.</description><subject>Adult</subject><subject>Aged</subject><subject>Antihyperglycaemics</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Diabetes Mellitus, Type 2 - psychology</subject><subject>Female</subject><subject>Glycated Hemoglobin A - analysis</subject><subject>Health technology assessment</subject><subject>Humans</subject><subject>Insulin</subject><subject>Insulin - therapeutic use</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Pharmacoeconomics</subject><subject>Quality of Life</subject><subject>Quality-of-life-rating-scales</subject><subject>Type-2-diabetes-mellitus</subject><issn>1170-7690</issn><issn>1179-2027</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><recordid>eNpNUMtOwzAQtBAIyuMXkE_cArt2E8dHVPEUEkKCs-U4myaQF3EC6t_jtlBx2J2Vd2Y1HsY4wqXAJL4CANQQywi1TnEOAqLwBOkemyEqHQkQan8zQ6QSDUfs2Pv3wEikEofsCAHTZJ7AjC1eJltX44p3Ba-rgnjR1XX3XbVLbrkrbbskXrV8LGmw_SpsB55XNqORPG-oDtLJn7KDwtaezn7xhL3d3rwu7qOn57uHxfVT5Oagxyi3GlyMrnBZqnOy0oIkdIAoE8xSJXIsLCaOMFa5FhZtYmPIJQXPscikPGEX27v90H1O5EfTVN4FE7albvJGQfi20mkgpluiGzrvBypMP1SNHVYGwawDNH8Bml2AZhNgkD5upQP15Ha674-yL8l1rfky0uI8tNV6COoAVSgRql8joBGgTDk24dj5r-Epayj_52Ibv_wByYKEOQ</recordid><startdate>19980801</startdate><enddate>19980801</enddate><creator>Pibernik-Okanović, M</creator><creator>Szabo, S</creator><creator>Metelko, Z</creator><general>Springer Healthcare | Adis</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>DKI</scope><scope>X2L</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19980801</creationdate><title>Quality of life following a change in therapy for diabetes mellitus</title><author>Pibernik-Okanović, M ; Szabo, S ; Metelko, Z</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c409t-da90c51cfcb89dea3a03e1c011361b872d1fa16ce157d92a1a6a50d3e37252b33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antihyperglycaemics</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Diabetes Mellitus, Type 2 - psychology</topic><topic>Female</topic><topic>Glycated Hemoglobin A - analysis</topic><topic>Health technology assessment</topic><topic>Humans</topic><topic>Insulin</topic><topic>Insulin - therapeutic use</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Pharmacoeconomics</topic><topic>Quality of Life</topic><topic>Quality-of-life-rating-scales</topic><topic>Type-2-diabetes-mellitus</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pibernik-Okanović, M</creatorcontrib><creatorcontrib>Szabo, S</creatorcontrib><creatorcontrib>Metelko, Z</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>RePEc IDEAS</collection><collection>RePEc</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>PharmacoEconomics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pibernik-Okanović, M</au><au>Szabo, S</au><au>Metelko, Z</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Quality of life following a change in therapy for diabetes mellitus</atitle><jtitle>PharmacoEconomics</jtitle><addtitle>Pharmacoeconomics</addtitle><date>1998-08-01</date><risdate>1998</risdate><volume>14</volume><issue>2</issue><spage>201</spage><epage>207</epage><pages>201-207</pages><issn>1170-7690</issn><eissn>1179-2027</eissn><abstract>The study objective was to evaluate and compare quality-of-life (QOL) parameters between patients with type 2 (non-insulin-dependent) diabetes mellitus who changed therapy from an oral hypoglycaemic agent (OHA) to insulin and those who remained on an OHA. The World Health Organization Quality of Life Questionnaire (WHOQOL) was used to assess quality of life among 2 groups of patients with type 2 diabetes mellitus at baseline and after a 2-month follow-up period. The study was conducted in the outpatient department of the Vuk Vrhovac Clinic, a referral centre for registration, treatment and follow-up of patients with diabetes mellitus in Zagreb, Croatia. 32 consecutively recruited patients with type 2 diabetes mellitus who were switched from an OHA to insulin therapy (group 1) were compared with 28 patients who remained on OHA (group 2) with respect to QOL issues. The patient groups were comparable in terms of gender, age, duration of disease, education and family status. However, patients in group 1 had glycosylated haemoglobin (HbA1c) values greater than 9.5% on average during a period of approximately 6 months, which was the criterion used for switching to insulin therapy. At baseline, various QOL ratings were higher among patients in group 2 than group 1, indicating better quality of life with respect to overall quality of life (t = -2.31, p = 0.03), physical health (t = -2.36, p = 0.02), psychological state (t = -2.01, p = 0.05) and level of independence (t = -2.75, p = 0.001), while no differences were found between groups with respect to the social domain, personal beliefs and environmental QOL aspects. After the follow-up period, the groups were comparable in all QOL aspects other than overall quality of life (t = -2.18, p = 0.03) and level of independence (t = -3.49, p = 0.001), both of which remained higher for patients in group 2. No changes in QOL parameters were detected within group 2 from baseline to the end of the 2-month follow-up period, whereas patients in group 1 showed significant improvement in psychological QOL determinants (t = -2.14, p = 0.04). Results of the study indicate that introducing insulin therapy in patients with type 2 diabetes mellitus and sustained elevated HbA1c levels might positively affect their quality of life.</abstract><cop>New Zealand</cop><pub>Springer Healthcare | Adis</pub><pmid>10186460</pmid><doi>10.2165/00019053-199814020-00008</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1170-7690
ispartof PharmacoEconomics, 1998-08, Vol.14 (2), p.201-207
issn 1170-7690
1179-2027
language eng
recordid cdi_proquest_miscellaneous_70027798
source Springer Nature:Jisc Collections:Springer Nature Read and Publish 2023-2025: Springer Reading List
subjects Adult
Aged
Antihyperglycaemics
Diabetes Mellitus, Type 2 - drug therapy
Diabetes Mellitus, Type 2 - psychology
Female
Glycated Hemoglobin A - analysis
Health technology assessment
Humans
Insulin
Insulin - therapeutic use
Male
Middle Aged
Pharmacoeconomics
Quality of Life
Quality-of-life-rating-scales
Type-2-diabetes-mellitus
title Quality of life following a change in therapy for diabetes mellitus
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T11%3A26%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Quality%20of%20life%20following%20a%20change%20in%20therapy%20for%20diabetes%20mellitus&rft.jtitle=PharmacoEconomics&rft.au=Pibernik-Okanovi%C4%87,%20M&rft.date=1998-08-01&rft.volume=14&rft.issue=2&rft.spage=201&rft.epage=207&rft.pages=201-207&rft.issn=1170-7690&rft.eissn=1179-2027&rft_id=info:doi/10.2165/00019053-199814020-00008&rft_dat=%3Cproquest_cross%3E70027798%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c409t-da90c51cfcb89dea3a03e1c011361b872d1fa16ce157d92a1a6a50d3e37252b33%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=70027798&rft_id=info:pmid/10186460&rfr_iscdi=true